Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
1.
J Enzyme Inhib Med Chem ; 34(1): 1178-1185, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31282230

ABSTRACT

The activation of the ß-class carbonic anhydrases (CAs, EC 4.2.1.1) from the bacteria Brucella suis and Francisella tularensis with amine and amino acids was investigated. BsuCA 1 was sensitive to activation with amino acids and amines, whereas FtuCA was not. The most effective BsuCA 1 activators were L-adrenaline and D-Tyr (KAs of 0.70-0.95 µM). L-His, L-/D-Phe, L-/D-DOPA, L-Trp, L-Tyr, 4-amino-L-Phe, dopamine, 2-pyridyl-methylamine, D-Glu and L-Gln showed activation constants in the range of 0.70-3.21 µM. FtuCA was sensitive to activation with L-Glu (KA of 9.13 µM). Most of the investigated compounds showed a weak activating effect against FtuCA (KAs of 30.5-78.3 µM). Many of the investigated amino acid and amines are present in high concentrations in many tissues in vertebrates, and their role in the pathogenicity of the two bacteria is poorly understood. Our study may bring insights in processes connected with invasion and pathogenic effects of intracellular bacteria.


Subject(s)
Amines/pharmacology , Amino Acids/pharmacology , Brucella suis/enzymology , Carbonic Anhydrases/metabolism , Enzyme Activation/drug effects , Francisella tularensis/enzymology , Amines/chemistry , Amino Acids/chemistry , Carbonic Anhydrases/genetics , Structure-Activity Relationship
2.
J Enzyme Inhib Med Chem ; 33(1): 255-259, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29271264

ABSTRACT

The two ß-carbonic anhydrases (CAs, EC 4.2.1.1) from the pathogenic bacterium Brucella suis, BsuCA1 and BsuCA2, were investigated for their inhibition profile with a series of pyridine-3-sulphonamide derivatives incorporating 4-hetaryl moieties. BsuCA1 was effectively inhibited by these sulphonamides with inhibition constants ranging between 34 and 624 nM. BsuCA2 was less sensitive to these inhibitors, with KIs in the range of 62 nM - > 10 µM. The nature of the 4-substituent present on the pyridine ring was the main factor influencing the inhibitory profile against both isoforms, with 4-halogenophenylpiperazin-1-yl and 3,4,5-trisubstituted-pyrazol-1-yl derivatives showing the most effective inhibition. Some of these sulphonamides were most effective bacterial CA than human (h) CA I and II inhibitors, making them selective for the prokaryotic enzymes. Investigation of bacterial CA inhibitors may be relevant for finding antibiotics with a new mechanism of action compared to the clinically used agents for which substantial drug resistance emerged.


Subject(s)
Brucella suis/enzymology , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Pyridines/pharmacology , Sulfonamides/pharmacology , Carbonic Anhydrase Inhibitors/chemical synthesis , Dose-Response Relationship, Drug , Humans , Molecular Structure , Pyridines/chemical synthesis , Pyridines/chemistry , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistry
3.
J Enzyme Inhib Med Chem ; 32(1): 683-687, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28274160

ABSTRACT

Carbonic anhydrases have started to emerge as new potential antibacterial targets for several pathogens. Two ß-carbonic anhydrases, denominated bsCA I and bsCA II, have been isolated and characterized from the bacterial pathogen Brucella suis, the causative agent of brucellosis or Malta fever. These enzymes have been investigated in detail and a wide range of classical aromatic and heteroaromatic sulfonamides as well as carbohydrate-based compounds have been found to inhibit selectively and efficiently Brucella suis carbonic anhydrases. Inhibition of these metalloenzymes constitutes a novel approach for the potential development of new anti-Brucella agents. This review aims at discussing the recent literature on this topic.


Subject(s)
Anti-Bacterial Agents/pharmacology , Brucella suis/drug effects , Brucella suis/enzymology , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Sulfonamides/pharmacology , Anti-Bacterial Agents/chemistry , Carbonic Anhydrase Inhibitors/chemistry , Dose-Response Relationship, Drug , Microbial Sensitivity Tests , Structure-Activity Relationship , Sulfonamides/chemistry
4.
Vaccine ; 34(13): 1524-1530, 2016 Mar 18.
Article in English | MEDLINE | ID: mdl-26899373

ABSTRACT

Brucellosis is one of the most widespread zoonosis in the world affecting many domestic and wild animals including bovines, goats, pigs and dogs. Each species of the Brucella genus has a particular tropism toward different mammals being the most relevant for human health Brucella abortus, Brucella melitensis and Brucella suis that infect bovines, goats/camelids and swine respectively. Although for B. abortus and B. melitensis there are vaccines available, there is no efficient vaccine to protect swine from B. suis infection so far. We describe here the construction of a novel vaccine strain that confers excellent protection against B. suis in a mouse model of infection. This strain is a clean deletion of the phosphoglucomutase (pgm) gene that codes for a protein that catalyzes the conversion of glucose-6-P to glucose-1-P, which is used as a precursor for the biosynthesis of many polysaccharides. The Delta-pgm strain lacks a complete lipopolysaccharide, is unable to synthesize cyclic beta glucans and is sensitive to several detergents and Polymyxin B. We show that this strain replicates in cultured cells, is completely avirulent in the mouse model of infection but protects against a challenge of the virulent strain inducing the production of pro-inflammatory cytokines. This novel strain could be an excellent candidate for the control of swine brucellosis, a disease of emerging concern in many parts of the world.


Subject(s)
Brucella Vaccine/immunology , Brucella suis/genetics , Brucellosis/prevention & control , Gene Deletion , Phosphoglucomutase/genetics , Animals , Antibodies, Bacterial/blood , Brucella suis/enzymology , Cell Line , Female , Gene Knockdown Techniques , HeLa Cells , Humans , Mice , Mice, Inbred BALB C , Vaccines, Attenuated/immunology , beta-Glucans/chemistry
5.
J Enzyme Inhib Med Chem ; 30(6): 1010-2, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25792504

ABSTRACT

We investigated a series of N-hydroxysulfamides obtained by Ferrier sulfamidoglycosylation for the inhibition of two bacterial carbonic anhydrases (CAs, EC 4.2.1.1) present in the pathogen Brucella suis. bsCA I was moderately inhibited by these compounds with inhibition constants ranging between 522 and 958 nM and no notable differences of activity between the acetylated or the corresponding deacetylated derivatives. The compounds incorporating two trans-acetates and the corresponding deprotected ones were the most effective inhibitors in the series. bsCA II was better inhibited, with inhibition constants ranging between 59.8 and 799 nM. The acetylated derivatives were generally better bsCA II inhibitors compared to the corresponding deacetylated compounds. Although these compounds were not highly isoform-selective CA inhibitors (CAIs) for the bacterial over the human CA isoforms, some of them possess inhibition profiles that make them interesting leads for obtaining better and more isoform-selective CAIs targeting bacterial enzymes.


Subject(s)
Aminoglycosides/pharmacology , Brucella suis/enzymology , Carbonic Anhydrase II/antagonists & inhibitors , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/pharmacology , Sulfonamides/pharmacology , Aminoglycosides/chemical synthesis , Aminoglycosides/chemistry , Carbonic Anhydrase I/metabolism , Carbonic Anhydrase II/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistry
6.
J Enzyme Inhib Med Chem ; 30(6): 1017-20, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25676329

ABSTRACT

A small series of C-glycosides containing the phenol moiety was tested for the inhibition of the ß-class carbonic anhydrases (ßCAs, EC 4.2.1.1) from Brucella suis. Many compounds showed activities in the micromolar or submicromolar range and excellent selectivity for pathogen CAs over human isozymes. Glycosides incorporating the 3-hydroxyphenyl moiety showed the best inhibition profile, and therefore this functionality represents lead for the development of novel anti-infectives with a new mechanism of action.


Subject(s)
Brucella suis/enzymology , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Glycosides/pharmacology , Phenols/pharmacology , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Dose-Response Relationship, Drug , Glycosides/chemistry , Molecular Structure , Phenols/chemistry , Structure-Activity Relationship
7.
J Enzyme Inhib Med Chem ; 30(5): 857-61, 2015.
Article in English | MEDLINE | ID: mdl-25291009

ABSTRACT

A small series of C-glycosides containing the methoxyaryl moieties was tested for the inhibition of the ß-class carbonic anhydrases (CAs, EC 4.2.1.1) from Cryptococcus neoformans and Brucella suis. Many compounds showed activities in the micromolar or submicromolar range and excellent selectivity for pathogen CAs over human isozymes. The deprotected glycosides incorporating the 6-methoxy-2-naphthyl moiety showed the best inhibition profile and therefore represent leads for the development of novel anti-infectives with a new mechanism of action.


Subject(s)
Brucella suis/enzymology , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Cryptococcus neoformans/enzymology , Glycosides/pharmacology , Naphthalenes/pharmacology , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Glycosides/chemical synthesis , Glycosides/chemistry , Humans , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Naphthalenes/chemistry
8.
Bioorg Med Chem Lett ; 24(21): 5008-10, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-25278235

ABSTRACT

Histidinol dehydrogenase (HDH) has been established as a virulence factor for the human pathogen bacterium Brucella suis. Targeting such a virulence factor is a relevant anti-infectious approach as it could decrease the frequency of antibiotic resistance appearance. In this paper, we describe the synthesis of a family of oxo- and thioxo-imidazo[1,5-c]pyrimidines, potential enzyme inhibitors. Beyond their anti-HDH activity, the synthesis approach of these molecules, never described before, is highly original and these oxo- and thioxo- derivatives can improve dramatically the efficiency of the histidine protection pathway for the synthesis of histidine analogues.


Subject(s)
Alcohol Oxidoreductases/antagonists & inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Brucella suis/enzymology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Histidine/chemistry , Small Molecule Libraries/pharmacology , Brucella suis/drug effects , Brucellosis/microbiology , Histidine/metabolism , Humans , Imidazoles/chemistry , Molecular Structure , Pyrimidines/chemistry , Small Molecule Libraries/chemical synthesis , Structure-Activity Relationship , Virulence Factors/chemical synthesis , Virulence Factors/pharmacology
9.
Biochimie ; 97: 114-20, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24140957

ABSTRACT

L-Histidinol dehydrogenase from Brucella suis (BsHDH) is an enzyme involved in the histidine biosynthesis pathway which is absent in mammals, thus representing a very interesting target for the development of anti-Brucella agents. In this paper we report the crystallographic structure of a mutated form of BsHDH both in its unbound form and in complex with a nanomolar inhibitor. These studies provide the first structural background for the rational design of potent HDH inhibitors, thus offering new hints for clinical applications.


Subject(s)
Alcohol Oxidoreductases/chemistry , Anti-Bacterial Agents/chemistry , Bacterial Proteins/chemistry , Brucella suis/chemistry , Butanones/chemistry , Enzyme Inhibitors/chemistry , Imidazoles/chemistry , Alcohol Oxidoreductases/antagonists & inhibitors , Alcohol Oxidoreductases/genetics , Amino Acid Sequence , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/genetics , Brucella suis/enzymology , Catalytic Domain , Crystallography, X-Ray , Drug Design , Escherichia coli/enzymology , Escherichia coli/genetics , Gene Expression , Histidine/chemistry , Histidine/metabolism , Molecular Docking Simulation , Molecular Sequence Data , Mutation , Protein Structure, Quaternary , Protein Structure, Secondary , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Sequence Alignment , Sequence Homology, Amino Acid
10.
BMC Genomics ; 14: 459, 2013 Jul 08.
Article in English | MEDLINE | ID: mdl-23834488

ABSTRACT

BACKGROUND: In the intracellular pathogen Brucella spp., the activation of the stringent response, a global regulatory network providing rapid adaptation to growth-affecting stress conditions such as nutrient deficiency, is essential for replication in the host. A single, bi-functional enzyme Rsh catalyzes synthesis and hydrolysis of the alarmone (p)ppGpp, responsible for differential gene expression under stringent conditions. RESULTS: cDNA microarray analysis allowed characterization of the transcriptional profiles of the B. suis 1330 wild-type and Δrsh mutant in a minimal medium, partially mimicking the nutrient-poor intramacrophagic environment. A total of 379 genes (11.6% of the genome) were differentially expressed in a rsh-dependent manner, of which 198 were up-, and 181 were down-regulated. The pleiotropic character of the response was confirmed, as the genes encoded an important number of transcriptional regulators, cell envelope proteins, stress factors, transport systems, and energy metabolism proteins. Virulence genes such as narG and sodC, respectively encoding respiratory nitrate reductase and superoxide dismutase, were under the positive control of (p)ppGpp, as well as expression of the cbb3-type cytochrome c oxidase, essential for chronic murine infection. Methionine was the only amino acid whose biosynthesis was absolutely dependent on stringent response in B. suis. CONCLUSIONS: The study illustrated the complexity of the processes involved in adaptation to nutrient starvation, and contributed to a better understanding of the correlation between stringent response and Brucella virulence. Most interestingly, it clearly indicated (p)ppGpp-dependent cross-talk between at least three stress responses playing a central role in Brucella adaptation to the host: nutrient, oxidative, and low-oxygen stress.


Subject(s)
Adaptation, Physiological/genetics , Bacterial Proteins/metabolism , Brucella suis/genetics , Brucella suis/physiology , Gene Expression Profiling , Stress, Physiological/genetics , Animals , Brucella suis/enzymology , Brucella suis/metabolism , Electron Transport Complex IV/genetics , Macrophages/cytology , Methionine/biosynthesis , Mice , Mutation , Nitrate Reductase/genetics , Oligonucleotide Array Sequence Analysis , Superoxide Dismutase/genetics , Up-Regulation , Vacuoles/microbiology
11.
J Biomol Struct Dyn ; 30(1): 125-36, 2012.
Article in English | MEDLINE | ID: mdl-22571438

ABSTRACT

Brucella suis is a dangerous biological warfare agent already used for military purposes. This bacteria cause brucellosis, a zoonosis highly infective and difficult to fight. An important selective target for chemotherapy against this disease is nucleoside hydrolase (NH), an enzyme still not found in mammals. We present here the first three-dimensional structure of B. suis NH (BsNH) and propose this enzyme as a molecular target to the drug design in the fight against brucellosis. In addition, we performed molecular docking studies, aiming to analyze the three-dimensional positioning of nine known inhibitors of Chritidia fasciculata NH (CfNH) in the active sites of BsNH and CfNH. We also analyzed the main interactions of some of these compounds inside the active site of BsNH and the relevant factors to biological activity. These results, together with further molecular dynamics (MD) simulations, pointed out to the most promising compound as lead for the design of potential inhibitors of BsNH. Most of the docking and MD results corroborated to each other and the docking results also suggested a good correlation with experimental data.


Subject(s)
Bacterial Proteins/chemistry , Brucella suis/enzymology , Molecular Dynamics Simulation , N-Glycosyl Hydrolases/chemistry , Amino Acid Sequence , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Biological Warfare Agents , Brucella suis/chemistry , Brucella suis/drug effects , Catalytic Domain , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Hydrogen Bonding , Kinetics , Molecular Sequence Data , N-Glycosyl Hydrolases/antagonists & inhibitors , N-Glycosyl Hydrolases/metabolism , Protein Binding , Reproducibility of Results , Sequence Alignment
12.
J Biol Chem ; 287(21): 17408-17414, 2012 May 18.
Article in English | MEDLINE | ID: mdl-22467878

ABSTRACT

TrwD, the VirB11 homologue in conjugative plasmid R388, is a member of the large secretion ATPase superfamily, which includes ATPases from bacterial type II and type IV secretion systems, type IV pilus, and archaeal flagellae assembly. Based on structural studies of the VirB11 homologues in Helicobacter pylori and Brucella suis and the archaeal type II secretion ATPase GspE, a unified mechanism for the secretion ATPase superfamily has been proposed. Here, we have found that the ATP turnover of TrwD is down-regulated by physiological concentrations of magnesium. This regulation is exerted by increasing the affinity for ADP, hence delaying product release. Circular dichroism and limited proteolysis analysis indicate that magnesium induces conformational changes in the protein that promote a more rigid, but less active, form of the enzyme. The results shown here provide new insights into the catalytic mechanism of the secretion ATPase superfamily.


Subject(s)
Adenosine Triphosphatases/metabolism , Bacterial Proteins/metabolism , Bacterial Secretion Systems/physiology , Brucella suis/enzymology , Helicobacter pylori/enzymology , Adenosine Triphosphatases/genetics , Bacterial Proteins/genetics , Brucella suis/genetics , Helicobacter pylori/genetics , Plasmids/genetics , Plasmids/metabolism
13.
J Inorg Biochem ; 110: 36-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22459172

ABSTRACT

The bacterial pathogen Brucella suis encodes two carbonic anhydrases (CAs, EC 4.2.1.1) belonging to the ß-class, bsCA1 and bsCA2, which are crucial for its life cycle. Sulfonamides, strong inhibitors of these enzymes, were shown to block the growth of the pathogen in vitro. Here we report the inhibition of these two CAs by inorganic and complex anions and other molecules interacting with zinc proteins, such as sulfamide, sulfamic acid, and phenylboronic/arsonic acids. The enzyme bsCA1 was inhibited in the low micromolar range by sulfamide, sulfamic acid, phenylboronic/arsonic acid, and in the submillimolar range by diethyldithiocarbamate. Isoform bsCA2 generally showed a stronger inhibition with most of these anions, with several low micromolar and many submillimolar inhibitors detected. Micromolar inhibition against bsCA2 was observed for sulfamide and sulfamic acid, whereas diethyldithiocarbamate, perruthenate, pyrovanadate, tellurate and phenylarsonic acid showed inhibition constants in the range of 0.29-1.52mM. These inhibitors may be used as leads for developing anti-Brucella agents with a diverse mechanism of action compared to clinically used antibiotics.


Subject(s)
Anions/chemistry , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Brucella suis/enzymology , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/chemistry
14.
J Inorg Biochem ; 111: 138-45, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22196018

ABSTRACT

Brucella, a facultative intracellular pathogen, is one of the most common zoonotic diseases worldwide. Considering the alarming health problem caused by the emergence of resistance and multi-resistance of intracellular pathogen, the challenge is currently to identify and to validate novel pharmaceutical targets in this bacteria species. Brucella's genome encodes metalloproteins involved in various biosynthetic processes, some of them being essential during intracellular growth phase and virulence. The potential of prokaryotic zinc metalloproteins such as carbonic anhydrase (CA) and histidinol dehydrogenase (HDH) as anti-Brucella targets has only recently been taken into consideration in the search of novel anti-infective agents that lack of cross-resistance to existing drugs. These enzymes have a growing significance in modern medicine as they are required for growth and/or virulence in several intracellular pathogen species. This review illustrates and describes the progress which has been made in the design and the discovery of selective inhibitors of these bacterial enzymes as new potential anti-Brucella agents.


Subject(s)
Alcohol Oxidoreductases/metabolism , Bacterial Proteins/metabolism , Brucella suis/enzymology , Carbonic Anhydrases/metabolism , Metalloproteins/metabolism , Zinc/metabolism , Alcohol Oxidoreductases/antagonists & inhibitors , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Brucella suis/drug effects , Brucella suis/pathogenicity , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Metalloproteins/antagonists & inhibitors , Molecular Structure , Virulence/drug effects
15.
Org Biomol Chem ; 9(10): 3681-90, 2011 May 21.
Article in English | MEDLINE | ID: mdl-21461427

ABSTRACT

In the facultative intracellular pathogen Brucella suis, histidinol dehydrogenase (HDH) activity, catalyzing the last step in histidine biosynthesis, is essential for intramacrophagic replication. The inhibition of this virulence factor by substituted benzylic ketones was a proof of concept that disarming bacteria leads to inhibition of intracellular bacterial growth in macrophage infection. This work describes the design, synthesis and evaluation of 19 new potential HDH inhibitors, using a combination of classical approaches and docking studies. The IC(50)-values of these inhibitors on HDH activity were in the nanomolar range, and several of them showed a 70-100% inhibition of Brucella growth in minimal medium. One selected compound yielded a strong inhibitory effect on intracellular replication of B. suis in human macrophages at concentrations as low as 5 µM, with an overall survival of intramacrophagic bacteria reduced by a factor 10(3). Docking studies with two inhibitors showed a good fitting in the catalytic pocket and also interaction with the second lipophilic pocket binding the cofactor NAD(+). Experimental data confirmed competition between inhibitors and NAD(+) at this site. Hence, these inhibitors can be considered as promising tools in the development of novel anti-virulence drugs.


Subject(s)
Alcohol Oxidoreductases/antagonists & inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Brucella suis/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Models, Molecular , Alcohol Oxidoreductases/chemistry , Alcohol Oxidoreductases/metabolism , Amino Acid Sequence , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/metabolism , Binding, Competitive , Brucella suis/enzymology , Brucella suis/pathogenicity , Brucella suis/physiology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/metabolism , Humans , Ketones/chemistry , Macrophages/drug effects , Macrophages/microbiology , Molecular Sequence Data , NAD/metabolism , Protein Conformation , Substrate Specificity , Virus Replication/drug effects
16.
Bioorg Med Chem ; 19(3): 1172-8, 2011 Feb 01.
Article in English | MEDLINE | ID: mdl-21251841

ABSTRACT

A ß-carbonic anhydrase (CA, EC 4.2.1.1) from the bacterial pathogen Brucella suis, bsCA II, has been cloned, purified, and characterized kinetically. bsCA II showed high catalytic activity for the hydration of CO(2) to bicarbonate, with a k(cat) of 1.1×10(6), and k(cat)/K(m) of 8.9×10(7)M(-1)s(-1). A panel of sulfonamides and sulfamates have been investigated for inhibition of this enzyme. All types of activities, from the low nanomolar to the micromolar, have been detected for these derivatives, which showed inhibition constants in the range of 7.3nM-8.56µM. The best bsCA II inhibitors were some glycosylated sulfanilamides, aliphatic sulfamates, and halogenated sulfanilamides, with inhibition constants of 7.3-87nM. Some of these dual inhibitors of bsCA I and II, also inhibited bacterial growth in vitro, in liquid cultures. These promising data on live bacteria allow us to propose bacterial ß-CA inhibition as an approach for obtaining anti-infective agents with a new mechanism of action compared to classical antibiotics.


Subject(s)
Anti-Bacterial Agents/pharmacology , Brucella suis/drug effects , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Sulfonamides/pharmacology , Sulfonic Acids/pharmacology , Anti-Bacterial Agents/chemistry , Brucella suis/enzymology , Brucella suis/growth & development , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/chemistry , Carbonic Anhydrases/genetics , Carbonic Anhydrases/isolation & purification , Cloning, Molecular , Drug Design , Drug Discovery , Inhibitory Concentration 50 , Kinetics , Sulfonamides/chemistry , Sulfonic Acids/chemistry
17.
Bioorg Med Chem Lett ; 20(7): 2178-82, 2010 Apr 01.
Article in English | MEDLINE | ID: mdl-20211561

ABSTRACT

A beta-carbonic anhydrase (CA, EC 4.2.1.1) from the bacterial pathogen Brucella suis, bsCA 1, has been cloned, purified characterized kinetically and for inhibition with a series of water soluble glycosylated sulfanilamides. bsCA 1 has appreciable activity as catalyst for the hydration of CO(2) to bicarbonate, with a k(cat) of 6.4x10(5) s(-1) and k(cat)/K(m) of 3.9x10(7) M(-1) s(-1). All types of inhibitory activities have been detected, with K(I)s in the range of 8.9-110 nM. The best bsCA 1 inhibitor were the galactose and ribose sulfanilamides, with inhibition constants of 8.9-9.2 nM. Small structural changes in the sugar moiety led to dramatic differences of enzyme inhibitory activity for this series of compounds. One of the tested glycosylsulfonamides and acetazolamide significantly inhibited the growth of the bacteria in cell cultures.


Subject(s)
Brucella suis/enzymology , Carbonic Anhydrase I/metabolism , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrase Inhibitors/pharmacology , Sulfanilamides/chemistry , Sulfanilamides/pharmacology , Amino Acid Sequence , Carbohydrates/chemistry , Carbonic Anhydrase I/antagonists & inhibitors , Carbonic Anhydrase I/chemistry , Humans , Kinetics , Molecular Sequence Data , Sequence Alignment , Structure-Activity Relationship , Water/chemistry
18.
J Med Chem ; 53(5): 2277-85, 2010 Mar 11.
Article in English | MEDLINE | ID: mdl-20158185

ABSTRACT

A beta-carbonic anhydrase (CA, EC 4.2.1.1) from the bacterial pathogen Brucella suis, bsCA 1, has been cloned, purified, and characterized kinetically. bsCA 1 has appreciable activity as catalyst for the hydration of CO(2) to bicarbonate, with a k(cat) of 6.4 x 10(5) s(-1) and k(cat)/K(m) of 3.9 x 10(7) M(-1).s(-1). A panel of 38 sulfonamides and one sulfamate have been investigated for inhibition of this new beta-CA. All types of activities have been detected, with K(I)s in the range of 17 nM to 5.87 microM. The best bsCA 1 inhibitors were ethoxzolamide (17 nM), celecoxib (18 nM), dorzolamide (21 nM), valdecoxib, and sulpiride (19 nM). Whether bsCA 1 inhibitors may have application in the fight against brucellosis, an endemic disease and the major bacterial zoonosis, producing debilitating infection in humans and animals, warrants further studies.


Subject(s)
Brucella suis/enzymology , Brucellosis/drug therapy , Carbonic Anhydrases/genetics , Phylogeny , Sulfonamides/pharmacology , Amino Acid Sequence , Animals , Base Sequence , Brucella suis/genetics , Carbonic Anhydrases/drug effects , Cloning, Molecular , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Humans , Kinetics , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Alignment , Sequence Analysis, DNA , Structure-Activity Relationship
19.
BMC Microbiol ; 8: 121, 2008 Jul 19.
Article in English | MEDLINE | ID: mdl-18638408

ABSTRACT

BACKGROUND: The sequenced genomes of the Brucella spp. have two urease operons, ure-1 and ure-2, but there is evidence that only one is responsible for encoding an active urease. The present work describes the purification and the enzymatic and phylogenomic characterization of urease from Brucella suis strain 1330. Additionally, the urease reactivity of sera from patients diagnosed with brucellosis was examined. RESULTS: Urease encoded by the ure-1 operon of Brucella suis strain 1330 was purified to homogeneity using ion exchange and hydrophobic interaction chromatographies. The urease was purified 51-fold with a recovery of 12% of the enzyme activity and 0.24% of the total protein. The enzyme had an isoelectric point of 5, and showed optimal activity at pH 7.0 and 28-35 degrees C. The purified enzyme exhibited a Michaelis-Menten saturation kinetics with a Km of 5.60 +/- 0.69 mM. Hydroxyurea and thiourea are competitive inhibitors of the enzyme with Ki of 1.04 +/- 0.31 mM and 26.12 +/- 2.30 mM, respectively. Acetohydroxamic acid also inhibits the enzyme in a competitive way. The molecular weight estimated for the native enzyme was between 130-135 kDa by gel filtration chromatography and 157 +/- 7 kDa using 5-10% polyacrylamide gradient non-denaturing gel. Only three subunits in SDS-PAGE were identified: two small subunits of 14,000 Da and 15,500 Da, and a major subunit of 66,000 Da. The amino terminal sequence of the purified large subunit corresponded to the predicted amino acid sequence encoded by ureC1. The UreC1 subunit was recognized by sera from patients with acute and chronic brucellosis. By phylogenetic and cluster structure analyses, ureC1 was related to the ureC typically present in the Rhizobiales; in contrast, the ureC2 encoded in the ure-2 operon is more related to distant species. CONCLUSION: We have for the first time purified and characterized an active urease from B. suis. The enzyme was characterized at the kinetic, immunological and phylogenetic levels. Our results confirm that the active urease of B. suis is a product of ure-1 operon.


Subject(s)
Brucella suis/classification , Brucella suis/enzymology , Urease/immunology , Urease/metabolism , Animals , Antibodies, Bacterial/blood , Brucella suis/drug effects , Brucella suis/immunology , Brucellosis/immunology , Enzyme Inhibitors/pharmacology , Humans , Kinetics , Phylogeny , Thiourea/pharmacology , Urease/classification
20.
J Enzyme Inhib Med Chem ; 23(3): 357-61, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18569340

ABSTRACT

Histidinol dehydrogenase (HDH, EC EC1.1.1.23) catalyses the final step in the biosynthesis of histidine and constitutes an attractive novel target for the development of new agents against the pathogenous, bacteria Brucella suis. A small library of new HDH inhibitors based on the L-histidinylphenylsulfonyl hydrazide scaffold has been synthesized and their inhibitory activity investigated. The obtained results demonstrate that modification of the group between the histidinyl moiety and the phenyl ring constitutes an important structural factor for the design of effective HDH inhibitors.


Subject(s)
Alcohol Oxidoreductases/antagonists & inhibitors , Anti-Bacterial Agents/chemistry , Brucella suis/enzymology , Enzyme Inhibitors/chemistry , Histidine/analogs & derivatives , Anti-Bacterial Agents/pharmacology , Azides , Enzyme Inhibitors/pharmacology , Histidine/pharmacology , Structure-Activity Relationship , Sulfones
SELECTION OF CITATIONS
SEARCH DETAIL
...